全国性横断面研究:乳房植入物重建中软组织支撑的使用与术后并发症
基于Epic Cosmos全国数据库66,862例乳房切除术后植入物重建患者,48.9%使用软组织支撑。调整年龄、BMI、吸烟和2型糖尿病后,使用软组织支撑与手术部位感染、血清肿、血肿、伤口裂开及植入物丢失的 odds 均升高,提示需重视患者选择与共同决策。
要点
- 使用软组织支撑者手术部位感染风险显著升高(aOR 3.89)。
- 软组织支撑与血清肿、血肿、伤口裂开及植入物丢失风险升高相关。
- 肥胖或吸烟等可干预合并症患者使用补片时尤需谨慎选择。
核心结论
- 在全国性队列中,乳房切除术后乳房重建使用软组织支撑与部分术后并发症风险升高相关。
研究设计与样本
- 基于Epic Cosmos全国数据库(超过3亿患者)的横断面研究,纳入2015至2025年因乳房切除术后植入物重建而植入乳房假体或组织扩张器(CPT 19340)的患者。
- 按是否使用软组织支撑(CPT 15777)分层,共纳入66,862例患者,其中32,680例(48.9%)使用软组织支撑,34,182例(51.1%)未使用。
- 主要结局为术后90天内并发症:手术部位感染、血清肿、血肿、伤口裂开及植入物丢失;计算各并发症的OR及95%CI,P<0.05为有统计学意义。
主要发现
- 使用软组织支撑者平均BMI更高(26.9±5.80 vs 26.5±5.74 kg/m²,P<0.05)。
- 当前吸烟者中使用软组织支撑的比例更低(3.7% vs 6.0%,P<0.05)。
- 调整年龄、BMI、吸烟状态及2型糖尿病后,软组织支撑与手术部位感染风险升高相关(aOR 3.89;95%CI 3.13-4.90;P<0.05)。
- 软组织支撑与血清肿(aOR 2.38;95%CI 2.07-2.73;P<0.05)、血肿(aOR 1.69;95%CI 1.46-1.95;P<0.05)风险升高相关。
- 软组织支撑与伤口裂开(aOR 2.58;95%CI 2.31-2.89;P<0.05)及植入物丢失(aOR 3.40;95%CI 3.00-3.88;P<0.05)风险升高相关。
临床怎么用
- 在乳房切除术后植入物重建中考虑使用软组织支撑时,应结合患者合并症进行个体化选择。
- 对肥胖或吸烟等可干预合并症患者,使用补片前需充分权衡并发症风险并开展共同决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Use of soft tissue support in postmastectomy, implant-based breast reconstruction (IBBR) has become increasingly common. Although soft tissue support (STS) offers benefits in terms of stability and contour, in some instances, its use has been associated with increased postoperative complications. This study assesses rates of postoperative complications following IBBR with and without soft tissue support in a large, nationwide database. METHODS: Using Epic Cosmos, a nationwide database of over 300 million patients, patients undergoing postmastectomy IBBR with implantation of a breast implant or tissue expander (CPT 19340) between 2015 and 2025 were identified. Patients were stratified by use of STS (CPT 15777). Primary outcomes included complications within 90 days of surgery: surgical site infection (SSI), seroma, hematoma, wound dehiscence, and implant loss. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated for each complication, and P < 0.05 was considered statistically significant. RESULTS: Among 66,862 patients undergoing IBBR, 32,680 (48.9%) received STS and 34,182 (51.1%) did not. Average BMI was higher in patients with STS (26.9 ± 5.80 vs 26.5 ± 5.74 kg/m 2 , P < 0.05). STS was used less frequently among current smokers (3.7% vs 6.0%, P < 0.05). Adjusting for age, BMI, smoking status, and type 2 diabetes status, STS use was associated with increased odds of surgical site infection (adjusted odds ratio [aOR], 3.89; 95% confidence interval [CI], 3.13-4.90; P < 0.05), seroma (aOR, 2.38; 95% CI, 2.07-2.73; P < 0.05), hematoma (aOR, 1.69; 95% CI, 1.46-1.95; P < 0.05), wound dehiscence (aOR, 2.58; 95% CI, 2.31-2.89; P < 0.05), and implant loss (aOR, 3.40; 95% CI, 3.00-3.88; P < 0.05). CONCLUSIONS: In this nationwide cohort, use of soft tissue support in postmastectomy breast reconstruction was associated with a higher risk of select postoperative complications. These findings underscore the importance of patient selection and shared decision making when considering mesh in breast reconstruction, particularly in patients with modifiable comorbidities such as obesity or smoking.
引用
- Lisk R, Hemal K, Boyd CJ, et al. Soft Tissue Support Use in Implant-Based Breast Reconstruction: A Nationwide, Cross-Sectional Study of Postoperative Complications. Ann Plast Surg. 2026. PMID: 41701186. doi:10.1097/SAP.0000000000004660
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。